Remdesevir and Hydroxychloroquine in moderate to severe Covid 19 patient.
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/02/031430
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
COVID RTPCR POSITIVE CASES
PNEUNONITIS AS EFIDENT FROM CXR, HRCT THORAX
REQUIRING OXYGEN VIA NRBM OR HIGHER SUPPORT LIKE HFNO,NIV OR INVASIVE VENTILATIO
Exclusion Criteria
H/O DRUG ALLERGY TO ANY OF THE STUDY DRUGS
H/O ADVERSE DRUG REACTION TO ANY OF THE STUDY DRUGS
ELEVATED LIVER ENZYMES
H/O OCCULAR DISEASE
H/O CARDIO VASCULAR CONDUCTION DISEASE
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AFEBRILE FOR 3 DAYS OR MORE <br/ ><br>RR 24/MIN OR LESS <br/ ><br>SPO2 94% OR MORE IN ROOM AIR <br/ ><br>NO RESPIRATORY DISTRESS, COUGH ETCTimepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method Morbidity if any <br/ ><br>Mortality if any <br/ ><br>Adverse reactionsTimepoint: 0-30DAYS